MedTrace Logo

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults

NCT01151319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-04-30

No results posted yet for this study

Summary

This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.

Conditions

  • HIV-1 Infections

Interventions

BIOLOGICAL

ChAdV63.HIVconsv low dose.

Attenuated chimp adenovirus. 5x10\^9 virus particles.

BIOLOGICAL

ChAdV63.HIVconsv high dose.

Attenuated chimp adenovirus at 5x10\^10 virus particles.

BIOLOGICAL

pSG2.HIVconsv

DNA at 4mg per dose.

BIOLOGICAL

MVA.HIVconsv

Attenuated poxvirus at 4x10\^8 plaque forming units per dose.

OTHER

Placebo

Phosphate buffered saline

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Tomas Hanke · University of Oxford

  • Lucy Dorrell · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151319 on ClinicalTrials.gov